AB0663 COMPARING METHODS FOR DETERMINING ANTIBODIES TO SARS-CoV-2 USING A RAPID TEST AND ENZYME-LINKED IMMUNOSORBENT ASSAY

Background: An accessible and sensitive method for determining antibodies to a new coronavirus infection is often the key timely provision of necessary medical care patients with rheumatic diseases Objectives: Compare methods SARS-CoV-2 using rapid test enzyme-linked immunosorbent assay (ELISA) Methods: Methods an express (Chromatographic IgG / IgM (Xiamen Biotime Biotechnology, China)) by ELISA (Reagent kit enzyme immunoassay class G immunoglobulins M (Vector-Best, Russia)) were compared. 80 included diagnosis rheumatoid arthritis 26 (33%), psoriatic - 9 (11%), osteoarthritis 15 (19%), heart disease 1 (1%), SLE 2 (3%), deramtomyositis 3 (4%), systemic sclerosis 5 (6%), connective tissue 4 (5%), including Sjogren’s syndrome, spondyloarthritis (19%). 17 (21%) denied history COVID-19 symptoms. 63 (79%) noted any signs 3.095 ± 1.45 months before (Median [2; 4] months). 109 43 days 111 [78; 135] The was considered standard. Results: When comparing results determination in serum, following obtained: sensitivity 99%. it among 66 samples negative result method, detected 6 cases ELISA/ So, 7.5% false negative. In 14 positive test, not detected. 3.75% false-positive. (Table 1). ELISA, 33%, specificity 85%. Table 1. Antibodies, express-test Antibodies (ELISA), absent present Row Totals 0 % 0.00% 100.00% 76 79 3.80% 96.20% 77 IgМ 60 90.91% 9.09% 11 78.57% 21.43% 71 Conclusion: Determination less reliable than ELISA. Disclosure Interests: None declared.